Literature DB >> 2564261

The cardiovascular effects of mivacurium chloride (BW B1090U) in patients receiving nitrous oxide-opiate-barbiturate anesthesia.

J J Savarese1, H H Ali, S J Basta, R P Scott, P B Embree, W B Wastila, M M Abou-Donia, C Gelb.   

Abstract

The dose-effect relationship of mivacurium chloride on arterial blood pressure, heart rate, and plasma histamine was determined in 97 consenting ASA physical status I-II patients receiving nitrous oxide-oxygen-opiate-barbiturate anesthesia. In the absence of surgical stimulation during steady state anesthetic conditions with controlled ventilation, average maximum change in tachograph-counted heart rate was 7% or less after 10-15-s injection of mivacurium at all doses from 0.03 to 0.30 mg/kg. Average peak change in mean arterial pressure measured via radial arterial catheter was 7% or less after all doses from 0.03 to 0.15 mg/kg. Transient (0.2-4.5 min) decreases in arterial blood pressure were noted after 10-15-s injection in some patients at 0.20, 0.25, and 0.30 mg/kg. When they occurred, these changes were usually accompanied by facial erythema lasting 2-5 min and were correlated with increases in plasma histamine level (P less than 0.001). Facial erythema, decrease in blood pressure, and elevation of histamine level were all accentuated by increasing the dose of mivacurium and by more rapid injection of the drug. For example, mean blood pressure decreased an average of 13% after injection of mivacurium 0.25 mg/kg over 10-15 s. In contrast, during administration over 30 and 60 s of this dose, arterial pressure decreased 7.6 and 1.5%, respectively (P less than 0.001, 10-15 s vs. 60-s injection). Average peak histamine level, which increased to 132% of control after administration of 0.25 mg/kg over 10-15 s, did not change after injection over 60 s.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2564261     DOI: 10.1097/00000542-198903000-00003

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  12 in total

1.  Hierarchical rule-based monitoring and fuzzy logic control for neuromuscular block.

Authors:  J S Shieh; S Z Fan; L W Chang; C C Liu
Journal:  J Clin Monit Comput       Date:  2000       Impact factor: 2.502

Review 2.  Monitoring, new drugs, and reversal of neuromuscular blocking drugs.

Authors:  D R Bevan
Journal:  Can J Anaesth       Date:  1991-05       Impact factor: 5.063

3.  Early neuromuscular recovery characteristics following administration of mivacurium plus vecuronium.

Authors:  R G Stout; S J Brull; D Kelly; D G Silverman
Journal:  Can J Anaesth       Date:  1996-04       Impact factor: 5.063

4.  Neuromuscular and cardiovascular effects of mivacurium chloride in surgical patients receiving nitrous oxide-narcotic or nitrous oxide-isoflurane anaesthesia.

Authors:  W W Choi; M P Mehta; D J Murray; M D Sokoll; R B Forbes; S D Gergis; M Abou-Donia; J Kirchner
Journal:  Can J Anaesth       Date:  1989-11       Impact factor: 5.063

5.  Speed and ease of tracheal intubation: priming with mivacurium compared with succinylcholine.

Authors:  L Molbegott; T Baker
Journal:  Can J Anaesth       Date:  1995-09       Impact factor: 5.063

6.  Succinylcholine.

Authors:  D R Bevan
Journal:  Can J Anaesth       Date:  1994-06       Impact factor: 5.063

Review 7.  Adverse effects of nondepolarising neuromuscular blocking agents. Incidence, prevention and management.

Authors:  M Abel; W J Book; J B Eisenkraft
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

Review 8.  Newer neuromuscular blocking drugs. An overview of their clinical pharmacology and therapeutic use.

Authors:  R K Mirakhur
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

Review 9.  Mivacurium. A review of its pharmacology and therapeutic potential in general anaesthesia.

Authors:  James E Frampton; Donna McTavish
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

10.  Neuroleptic malignant syndrome and mivacurium: a safe alternative to succinylcholine?

Authors:  D Kelly; S J Brull
Journal:  Can J Anaesth       Date:  1994-09       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.